William Blair Has Negative Forecast for APLS Q2 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report issued on Wednesday, May 7th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of ($0.52) for the quarter, down from their previous forecast of ($0.21). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at ($0.60) EPS.

Other research analysts have also recently issued reports about the company. The Goldman Sachs Group dropped their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Scotiabank dropped their target price on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Royal Bank of Canada dropped their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Raymond James cut Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and dropped their target price for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Finally, Bank of America cut Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $40.42.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock traded up $1.03 during trading on Monday, hitting $17.39. 749,744 shares of the company's stock traded hands, compared to its average volume of 2,229,578. The stock has a market capitalization of $2.18 billion, a P/E ratio of -8.55 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business has a 50-day simple moving average of $20.48 and a 200-day simple moving average of $26.77. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $149.90 million for the quarter, compared to analysts' expectations of $197.61 million. During the same period last year, the business earned ($0.54) earnings per share. The company's quarterly revenue was down 3.2% on a year-over-year basis.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its stake in Apellis Pharmaceuticals by 9.4% in the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock worth $691,000 after acquiring an additional 1,864 shares during the last quarter. KBC Group NV lifted its stake in shares of Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company's stock valued at $3,328,000 after purchasing an additional 101,655 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at approximately $445,000. Barclays PLC lifted its stake in shares of Apellis Pharmaceuticals by 18.0% in the 3rd quarter. Barclays PLC now owns 255,897 shares of the company's stock valued at $7,381,000 after purchasing an additional 39,019 shares during the last quarter. Finally, Merit Financial Group LLC bought a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at approximately $254,000. Institutional investors own 96.29% of the company's stock.

Insider Activity at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.50% of the stock is owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).